Want to see CANF full AI Analyst Report?
Can-Fite BioPharma (CANF) Ratios
660 Followers
Can-Fite BioPharma Ratios
CANF's free cash flow for Q2 2026 was $-2.66M. For the 2026 fiscal year, CANF's free cash flow was decreased by $-500.00 and operating cash flow was $-2.66M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.46 | 4.38 | 4.90 | 3.66 | 7.35 |
| Quick Ratio | 3.46 | 4.38 | 4.90 | 3.68 | 7.37 |
| Cash Ratio | 2.02 | 2.35 | 2.12 | 1.19 | 1.61 |
| Solvency Ratio | -2.52 | -2.14 | -2.03 | -2.11 | -2.14 |
| Operating Cash Flow Ratio | -3.30 | -3.72 | -4.18 | -4.32 | -3.61 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -312.59 | -225.02 | -186.00 |
| Net Current Asset Value | $ 5.52M | $ 5.30M | $ 6.16M | $ 4.35M | $ 14.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.70 | 1.68 | 1.60 | 2.08 | 1.41 |
| Debt Service Coverage Ratio | -709.00 | -580.21 | -199.51 | -157.53 | -180.68 |
| Interest Coverage Ratio | -710.72 | -580.71 | -585.36 | -631.04 | -713.44 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.02 | 0.25 | 0.57 | 1.86 |
| Net Debt to EBITDA | 0.55 | 0.58 | 0.52 | 0.29 | 0.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 94.07% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -2456.80% | -1206.23% | -1102.96% | -1246.42% | -1505.51% |
| EBITDA Margin | -2450.87% | -1205.19% | -1100.94% | -1244.69% | -1503.87% |
| Operating Profit Margin | -2456.80% | -1206.23% | -1102.96% | -1246.42% | -1505.51% |
| Pretax Profit Margin | -2426.67% | -1169.14% | -1027.46% | -1255.93% | -1478.90% |
| Net Profit Margin | -2426.67% | -1169.14% | -1027.46% | -1255.93% | -1476.55% |
| Continuous Operations Profit Margin | -2426.67% | -1169.14% | -1027.46% | -1255.93% | -1478.90% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 99.84% |
| EBT Per EBIT | 98.77% | 96.92% | 93.15% | 100.76% | 98.23% |
| Return on Assets (ROA) | -104.12% | -86.40% | -76.42% | -109.59% | -62.19% |
| Return on Equity (ROE) | -177.15% | -144.96% | -122.28% | -227.48% | -87.57% |
| Return on Capital Employed (ROCE) | -147.86% | -115.03% | -102.84% | -148.89% | -73.29% |
| Return on Invested Capital (ROIC) | -146.65% | -114.17% | -102.14% | -146.81% | -72.85% |
| Return on Tangible Assets | -104.12% | -86.40% | -76.42% | -109.59% | -62.19% |
| Earnings Yield | -2.00% | -3.33% | -81.42% | -61.33% | -63.83% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.52 | 0.00 | 9.53 | 17.23 | 17.77 |
| Payables Turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 5.52 | 4.88 | 9.17 | 6.43 | 4.61 |
| Asset Turnover | 0.04 | 0.07 | 0.07 | 0.09 | 0.04 |
| Working Capital Turnover Ratio | 0.06 | 0.09 | 0.10 | 0.07 | 0.07 |
| Cash Conversion Cycle | -17451.74 | 0.00 | 38.32 | 21.18 | 20.54 |
| Days of Sales Outstanding | 66.16 | 0.00 | 38.32 | 21.18 | 20.54 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 17517.90 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 66.16 | 0.00 | 38.32 | 21.18 | 20.54 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.07 | -1.05 | -39.61 | -79.44 | -128.90 |
| Free Cash Flow Per Share | -0.07 | -1.05 | -39.62 | -79.50 | -129.04 |
| Dividend Paid and CapEx Coverage Ratio | -4469.77 | -1527.40 | -4220.00 | -1200.11 | -896.18 |
| Capital Expenditure Coverage Ratio | -4469.77 | -1527.40 | -4220.00 | -1200.11 | -896.18 |
| Operating Cash Flow Coverage Ratio | -127.05 | -73.43 | -211.00 | -174.21 | -79.50 |
| Operating Cash Flow to Sales Ratio | -22.10 | -11.33 | -11.36 | -13.33 | -11.56 |
| Free Cash Flow Yield | -1.83% | -3.23% | -90.04% | -65.17% | -50.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -49.88 | -30.01 | -1.23 | -1.63 | -1.57 |
| Price-to-Sales (P/S) Ratio | 1211.03 | 350.86 | 12.62 | 20.48 | 23.13 |
| Price-to-Book (P/B) Ratio | 88.41 | 43.50 | 1.50 | 3.71 | 1.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -54.79 | -30.94 | -1.11 | -1.53 | -2.00 |
| Price-to-Operating Cash Flow Ratio | -54.81 | -30.97 | -1.11 | -1.54 | -2.00 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | 0.75 | 0.02 | 0.03 | 0.05 |
| Enterprise Value Multiple | -48.87 | -28.53 | -0.63 | -1.36 | -1.21 |
| Enterprise Value | 488.90M | 231.76M | 5.14M | 13.67M | 15.47M |
| EV to EBITDA | -48.87 | -28.53 | -0.63 | -1.36 | -1.21 |
| EV to Sales | 1197.66 | 343.86 | 6.91 | 16.88 | 18.13 |
| EV to Free Cash Flow | -54.19 | -30.33 | -0.61 | -1.26 | -1.57 |
| EV to Operating Cash Flow | -54.20 | -30.35 | -0.61 | -1.27 | -1.57 |
| Tangible Book Value Per Share | 0.05 | 0.75 | 29.30 | 32.89 | 188.05 |
| Shareholders’ Equity Per Share | 0.05 | 0.75 | 29.30 | 32.89 | 188.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.09 | 3.49 | 5.96 | 11.15 |
| Net Income Per Share | -0.08 | -1.09 | -35.83 | -74.82 | -164.68 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.99 | 0.97 | 0.93 | 1.01 | 0.98 |
| Research & Development to Revenue | 16.53 | 8.54 | 8.05 | 9.58 | 11.55 |
| SG&A to Revenue | 8.98 | 4.52 | 3.98 | 3.88 | 4.51 |
| Stock-Based Compensation to Revenue | 0.83 | 0.54 | 0.35 | 0.32 | 0.55 |
| Income Quality | 0.92 | 0.97 | 1.11 | 1.06 | 0.78 |
Currency in USD
